内毒素清除在內毒素血症性脓毒性休克中的重要性:EUPHRATES 随机对照试验的事后分析
该研究为 EUPHRATES 多中心随机对照试验的事后分析,纳入北美 55 家三级医院中脓毒性休克、内毒素活性测定 0.60–0.90 且多器官功能障碍综合征评分大于 9 的 194 例患者(多黏菌素 B 组 88 例,假治疗组 106 例)。以第 3 天较基线内毒素活性测定的中位下降幅度(10.4%)及第 3 天目标内毒素活性测定水平(小于 0.65)两种方式评估内毒素清除与结局的关系。内毒素活性下降超过中位数的患者中,多黏菌素 B 组死亡率有降低趋势(17.1% vs 33.3%,p=0.07),无机械通气天数显著增加(20 vs 13.5,p=0.04),压力校正心率显著改善(p=0.02)。第 3 天内毒素活性测定小于 0.65 的患者中,多黏菌素 B 组死亡率有降低趋势(16% vs 33%,p=0.06),无通气天数显著增加(20 vs 16,p=0.05),Kaplan-Meier 分析显示多黏菌素 B 组死亡率降低 17%(p=0.04)。作者认为这些发现属假设生成,需前瞻性验证。
要点
- 在脓毒性休克且内毒素活性测定 0.60–0.90、多器官功能障碍综合征评分大于 9 的患者中,多黏菌素 B 组第 3 天内毒素活性下降超过中位数(10.4%)者死亡率有降低趋势(17.1% vs 33.3%,p=0.07)。
- 内毒素活性下降超过中位数的患者中,多黏菌素 B 组无机械通气天数显著多于假治疗组(20 vs 13.5,p=0.04)。
- 第 3 天内毒素活性测定小于 0.65 的患者中,多黏菌素 B 组死亡率有降低趋势(16% vs 33%,p=0.06),无通气天数显著增加(20 vs 16,p=0.05)。
- Kaplan-Meier 分析显示多黏菌素 B 组死亡率降低 17%(p=0.04)。
- 作者认为上述结果属假设生成,需前瞻性验证。
适用人群与场景
- 脓毒性休克且内毒素活性测定大于或等于 0.60 至小于 0.90、多器官功能障碍综合征评分大于 9 的患者。
- 来自北美 55 家三级医院的多中心随机对照试验人群。
诊断标准与关键阈值
- 基线内毒素活性测定大于或等于 0.60 至小于 0.90。
- 多器官功能障碍综合征评分大于 9。
- 第 3 天内毒素活性测定目标水平小于 0.65。
- 内毒素活性测定较基线下降幅度以中位数 10.4% 为界。
处置流程与药物剂量
- 多黏菌素 B 血液灌流治疗两次或假治疗。
研究设计与关键结果
- 事后分析纳入 194 例患者(多黏菌素 B 组 88 例,假治疗组 106 例)。
- 人群内毒素活性测定中位下降幅度为 10.4%。
- 内毒素活性下降超过中位数的患者中,多黏菌素 B 组死亡率 17.1% vs 假治疗组 33.3%(p=0.07),无机械通气天数 20 vs 13.5(p=0.04),压力校正心率显著改善(p=0.02)。
- 第 3 天内毒素活性测定小于 0.65 的患者中,多黏菌素 B 组死亡率 16% vs 假治疗组 33%(p=0.06),无通气天数 20 vs 16(p=0.05)。
- Kaplan-Meier 分析显示多黏菌素 B 组死亡率降低 17%(p=0.04)。
证据类型、等级与局限
- 证据类型:多中心随机对照临床试验的事后分析。
- 作者认为这些发现属假设生成,需前瞻性验证。
对床旁实践的改变
- 作者认为,以中位下降幅度或设定治疗目标来评估多黏菌素 B 降低内毒素活性测定水平,可能改善死亡率和器官功能结局。
- 作者认为这些发现属假设生成,需前瞻性验证。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: To investigate the relationship between survival and treatment-related reduction in endotoxin activity for patients in the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock trial with baseline endotoxin activity assay greater than or equal to 0.60 to less than 0.90 units.
DESIGN: Post hoc analysis of a multicenter randomized controlled clinical trial.
SETTING: Fifty-five tertiary hospitals in North America.
PATIENTS: Patients with septic shock and endotoxin activity assay level greater than or equal to 0.60 to less than 0.90 and multiple organ dysfunction syndrome greater than 9.
INTERVENTIONS: Two polymyxin B hemoperfusion treatments or Sham.
MEASUREMENTS AND MAIN RESULTS: One-hundred ninety-four patients were included (88 polymyxin B and 106 Sham). We evaluated the impact of changes in endotoxin activity assay based on comparison to the median reduction from baseline to day 3 and a second method where a target post-treatment endotoxin activity assay level (day 3) was established. The population median reduction in endotoxin activity assay level was 10.4%. In patients with a greater than median reduction, there was trend toward lower mortality with polymyxin B (17.1% vs 33.3%; p = 0.07) and a significant increase in mechanical ventilation-free days (20 vs 13.5; p = 0.04). The pressure adjusted heart rate showed a significant improvement in the polymyxin B group (p = 0.02). For patients who achieved an endotoxin activity assay of less than 0.65 at day 3, the polymyxin B treated group had a trend toward a mortality reduction compared to Sham (16% vs 33%;p = 0.06) and a significant increase in ventilation-free day (20 vs 16; p = 0.05). Kaplan-Meier analysis showed a 17% reduction in mortality with polymyxin B (p = 0.04).
CONCLUSIONS: These findings suggest that reducing endotoxin activity assay levels with polymyxin B as measured by comparison to a median reduction or when a treatment target is established, may result in improvements in mortality and organ function outcomes. This article is the first to report endotoxin activity assay measurements in response to polymyxin B use versus Sham in patients with septic shock and elevated endotoxin activity assay. These findings are considered to be hypothesis generating and will need to be prospectively validated.
参考来源
- Rachoin JS, Foster D, Giese R, et al. Importance of Endotoxin Clearance in Endotoxemic Septic Shock: An Analysis From the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemic Septic Shock (EUPHRATES) Trial. Crit Care Explor. 2020. PMID: 32211615. doi:10.1097/CCE.0000000000000083
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。